EDP Sciences logo
Web of Conferences logo
Search
Menu
All issues Volume 619 (2025) E3S Web Conf., 619 (2025) 05004 References
Open Access
Issue
E3S Web Conf.
Volume 619, 2025
3rd International Conference on Sustainable Green Energy Technologies (ICSGET 2025)
Article Number 05004
Number of page(s) 17
Section Nanotechnology Innovations in Energy, Environment, and Healthcare
DOI https://doi.org/10.1051/e3sconf/202561905004
Published online 12 March 2025
  1. Keck CM and Muller RH. 2006. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 62(1): 3-16. [CrossRef] [PubMed] [Google Scholar]
  2. Kesisoglou F and Mitra A. 2012. Crystalline nanosuspensions as potential toxicology and clinical oral formulations for BCS II / IV compounds. AAPS J14(4): 677-687. [CrossRef] [PubMed] [Google Scholar]
  3. Verma S,Kumar S, Gokhale R, Burgess DJ. 2011. Physical stability of nanosuspensions: investigation of the role of stabilizers on ostwald ripening. Int J Pharmceut 406(1-2): 145–152. [CrossRef] [Google Scholar]
  4. Junghanns AH and Muller RH. 2008. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed3(3): 295–310. [Google Scholar]
  5. Kesisoglou F, Panmai S, Wu Y. 2007. Nanosizing--oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 59(7): 631–44. [CrossRef] [PubMed] [Google Scholar]
  6. Che E, Zheng X, Sun C, Chang D, Jiang T, Wang S. 2012. Drug nanocrystals : a state of the art formulation strategy for preparing the poorly water-soluble drugs. Asian J Pharm Sci 7(2): 85–95. [Google Scholar]
  7. Gao L, Zhang ED, Chen EM. 2008. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanopart Res10(5): 845–62. [CrossRef] [Google Scholar]
  8. Patil MN and Pandit AB. 2007. Cavitation--a novel technique for making stable nano-suspensions. Ultrason Sonochem 14(5): 519–30. [CrossRef] [PubMed] [Google Scholar]
  9. Shariare MH, Altamimi MA, Marzan AL, Tabassum R, Jahan B, Reza HM, Rahman M, Ahsan GU, & Kazi M. 2019. In vitro dissolution and bioavailability study of furosemide nanosuspension prepared using design of experiment (DoE). Saudi Pharm J, 27(1), 96–105. https://doi.org/10.1016/j.jsps.2018.09.002 [CrossRef] [PubMed] [Google Scholar]
  10. Mastiholimath VS, Bhagat AR, Mannur VS, Dandagi PM, Gadad AP, & Khanal P. 2020. Formulation and evaluation of cefixime nanosuspension for the enhancement of oral bioavailability by solvent-antisolvent method and its suitable method development. Indian J. Pharm Edu Res, 54(1), 55–67. https://doi.org/10.5530/ijper.54.1.7 [Google Scholar]
  11. Sattar A, Chen D, Jiang L, Pan Y, Tao Y, Huang L, Liu Z, Xie S, & Yuan Z. 2017. Preparation, characterization and pharmacokinetics of Cyadox nanosuspension. Sci Rep, 7(1). https://doi.org/10.1038/s41598-017-02523-4 [CrossRef] [Google Scholar]
  12. O’ Neil MJ, Heckelman PE, Koch CB, Roman KJ, Kenny CM and D’Arecca MR (Eds). 2006. Ziprasidone Hydrochloride, In: The Merck Index – An encyclopedia of chemicals, drugs and biological. Merck Research Laboratory, Division of Merck & Co., Inc., Whitehouse Station, New Jersey. 14th Ed., pp 10307. [Google Scholar]
  13. Sweetman SC. 2009. Ziprasidone Hydrochloride, In: Martindale - The Complete Drug Reference. Pharmaceutical Press, London.36thEd., pp 1036. [Google Scholar]
  14. Miceli JJ et al. 2005. Pharmacokinetics, safety, and tolerability of intramuscular Ziprasidone in healthy volunteers. J Clin Pharmacol 45: 620–30. [CrossRef] [PubMed] [Google Scholar]
  15. Preskorn SH. 2005. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. Clin Pharmacokinet 44: 1117–33. [CrossRef] [PubMed] [Google Scholar]
  16. Miceli JJ et al. 2000. The effects of ketoconazole on ziprasidone pharmacokinetics - a placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol49(S1): 71–76. [CrossRef] [Google Scholar]
  17. Martini LG and Crowley PJ. 2011. Controlling drug release in oral product development programs : An industrial Perspective, In: Controlled release in oral drug delivery. Springer, New York. 14thEd., pp 49-69. [CrossRef] [Google Scholar]
  18. Hassan MA, Suleiman MS and Najib NM. 1990. Improvement of the in-vitro dissolution characteristics of famotidine by inclusion in β- cyclodextrin. Int J Pharm 58: 19–24. [CrossRef] [Google Scholar]
  19. Rania HF and Mohammed AK. 2008. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: In-vitro and in-vivo evaluation. Eur J Pharm Biopharm 69: 993–1003. [CrossRef] [PubMed] [Google Scholar]
  20. Xia D, Quan P and Piao H. 2010. Preparation of stable nitrendipine nanosuspensions using the precipitation–ultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci 40: 325-334. [CrossRef] [PubMed] [Google Scholar]
  21. Pignatello R,Bucolo C, Spedalieri G, Maltese A, Puglisi G. 2002. Flurbiprofen- loaded acrylate polymer nanosuspensions for ophthalmic application. Biomater23(15): 3247–3255. [CrossRef] [Google Scholar]
  22. Armstrong NC and James KC. 1996. Pharmaceutical experimental design and interpretation. Bristol, PA, USA: Taylor and Francis Publications. [Google Scholar]
  23. Shinde SS and Hosmani AH, 2014. Preparation and evaluation of nanosuspensions for enhancing the Dissolution of lornoxicam by anti-solvent precipitation technique. Indo Am J Pharm Res 4(01): 398-405. [Google Scholar]
  24. Muller RH, Jacobs C and Kayser O. 2001. Nanosuspensions as particulate drug formulations in therapy Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 47: 3–19. [CrossRef] [PubMed] [Google Scholar]
  25. Wei L, Yonggang Y, Yongshou T, Xinlan X, Yang C, Liwei M, Yaqiong Z, Liang F. 2011. Preparation and in-vitro/in-vivo evaluation of Revaprazan Hydrochloride nanosuspension. Int J Pharmaceut408(1-2): 157–162. [CrossRef] [Google Scholar]
  26. Krishnamoorthy, Murugaperumal, P. Ajay-D-Vimal Raj, N. P. Subramaniam, M. Sudhakaran, and Arulselvi Ramasamy. “Design and development of optimal and deep-learning-based demand response technologies for residential hybrid Renewable Energy Management System.” Sustainability 15, no. 18 (2023): 13773. [CrossRef] [Google Scholar]
  27. ICH Harmonised Tripartite Guideline, Guideline for Residual Solvents, Q3C (R6). [http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/ Q3C/Q3C_R6Step_4.pdf] [Google Scholar]
  28. ICH Harmonised Tripartite Guideline, Stability Testing of New Drug Substances and Products, Q1A (R2). [http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2Guideline.pdf] [Google Scholar]
  29. Jan M, Georg A, Herbert P, Rainer M. 2004. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm 58: 615-619. [CrossRef] [PubMed] [Google Scholar]
  30. Lindenberg M, Knopp S and Dressman JB. 2004. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm58: 265-78. [CrossRef] [PubMed] [Google Scholar]
  31. Thakkar HP, Patel BV and Thakkar SP. 2011. Development and characterization of nanosuspensions of Olmesartan Medoxomil for bioavailability enhancement. J Pharm Bioallied Sci 3(3): 426–434. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.